Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular antigen processing

Point mutations in oncogene products such as ras may create neoantigenic determinants recognizable by T lymphocytes as tumor antigens, that could be marshalled to eliminate a tumor by inducing specific cytotoxic T lymphocytes (CTL) with an appropriate vaccine. Peptide-pulsed dendritic cells are a pr...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	International immunology 1997-08, Vol.9 (8), p.1085-1093
Hauptverfasser:	Smith, M C, Pendleton, C D, Maher, V E, Kelley, M J, Carbone, D P, Berzofsky, J A
Format:	Artikel
Sprache:	eng
Schlagworte:	Antigen Presentation - immunology Binding Sites Cancer Vaccines - immunology Cell Culture Techniques Epitopes - genetics Epitopes - immunology HLA-A2 Antigen - immunology HLA-A2 Antigen - metabolism Humans Peptides - immunology Peptides - metabolism Point Mutation ras Proteins - genetics ras Proteins - immunology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!